Share Purchase by Directors

RNS Number : 3953A

Redx Pharma plc

27 December 2017

 

REDX PHARMA PLC

("Redx" or "the Company")

Share Purchases by Directors

Alderley Park, December 27 2017- Redx Pharma (AIM:REDX), the drug discovery and development company, announces that it has been notified that Iain Ross, Executive Chairman, has on Friday 22 December acquired 102,000 Redx ordinary shares at a price of 20.75 pence per share.  Following this, Mr Ross will hold 450,000 ordinary shares in the Company, representing 0.36 per cent. of the issued share capital.

The Company also announces that Non-Executive Director Mr Peter Presland has on Friday 22 December acquired 120,000 Redx ordinary shares at a price of 22 pence per share. Mr Presland purchased the shares through his self-invested personal pension (SIPP).  Following this, Mr Presland will hold 120,000 ordinary shares in the Company, representing 0.09 per cent of the issued share capital.

The Company also announces that Non-Executive Director Dr Bernhard Kirschbaum has today acquired 50,000 Redx ordinary shares at a price of 21 pence per share. Following this, Dr Kirschbaum will hold 50,000 ordinary shares in the Company, representing 0.04 per cent of the issued share capital.

For further information, please contact:

Redx Pharma Plc	T: [phone]
Iain Ross, Executive Chairman
Cantor Fitzgerald Europe (Nominated Advisor & Broker)	T: [phone]
Phil Davies
WG Partners LLP (Joint Broker)	T: [phone]
Claes Spång/ Chris Lee/ David Wilson
FTI Consulting	T: [phone]
Simon Conway/Stephanie Cuthbert

About Redx Pharma

Redx Pharma discovers and develops proprietary, small molecule drugs to address areas of high unmet medical need in cancer and fibrosis. In cancer, Redx pursues targeted therapies where a biomarker can potentially be used for selecting those patients that are most likely to benefit from therapy, and/or drugs that are designed to disrupt cancer resistance pathways. In fibrosis, the Company is focused on developing treatments that will stop and reverse the formation of fibrotic tissue. In both therapeutic areas Redx's aim is to develop drugs whose profile suggests they will be best in class, if not first in class.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Iain Ross
2	Reason for notification
a.	Position/Status	Executive Chairman
b.	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Redx Pharma Plc
b.	LEI	213800HMS4EBXO589Y37
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary Shares of 1p each ISIN: GB00BSNB6S51
b.	Nature of the transaction	Purchase
c.	Price(s) and volume(s)	102,000 20.75 pence
d.	Aggregated information - Aggregated Volume - Price	N/A - Single Transaction
e.	Date of the transaction	22/12/17
f.	Place of the transaction	Outside of trading venue

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Peter Presland
2	Reason for notification
a.	Position/Status	Non-executive Director
b.	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Redx Pharma Plc
b.	LEI	213800HMS4EBXO589Y37
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary Shares of 1p each ISIN: GB00BSNB6S51
b.	Nature of the transaction	Purchase
c.	Price(s) and volume(s)	120,000 22 pence
d.	Aggregated information - Aggregated Volume - Price	N/A - Single Transaction
e.	Date of the transaction	22/12/17
f.	Place of the transaction	Outside of trading venue

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Bernhard Kirschbaum
2	Reason for notification
a.	Position/Status	Non-executive Director
b.	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Redx Pharma Plc
b.	LEI	213800HMS4EBXO589Y37
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary Shares of 1p each ISIN: GB00BSNB6S51
b.	Nature of the transaction	Purchase
c.	Price(s) and volume(s)	50,000 21 pence
d.	Aggregated information - Aggregated Volume - Price	N/A - Single Transaction
e.	Date of the transaction	27/12/17
f.	Place of the transaction	Outside of trading venue

 

END

 

 

DSHOKODQOBDDNBB